Indiana PREGMED
印第安纳预科
基本信息
- 批准号:8600300
- 负责人:
- 金额:$ 88.93万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-02-01 至 2015-12-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdverse effectsAffectAlcohol consumptionAntidepressive AgentsBiochemicalBioethicsBioinformaticsBiological MarkersBlood VesselsCYP2C19 geneCYP2C9 geneCYP2D6 geneCYP3A4 geneCYP3A5 geneCaringChildClinicalClinical PharmacologyClinical ResearchDataData SetDisciplineDiscipline of obstetricsDiseaseDoseDrug KineticsEnvironmentEnzymesExposure toFetusFluoxetineGenesGenetic PolymorphismGoalsHTR2A geneIncidenceIndianaInfantInfant DevelopmentInstitutional Review BoardsKnowledgeLaboratoriesLeadLinkMeasuresMental DepressionMetabolismModelingMothersNeonatalNeonatologyOutcomePathway interactionsPatientsPharmaceutical PreparationsPharmacodynamicsPharmacogeneticsPharmacogenomicsPharmacologyPlasmaPopulationPostpartum DepressionPregnancyPregnancy OutcomePregnant WomenPrevalencePrincipal InvestigatorRecording of previous eventsResearchResearch DesignRiskSafetySamplingSelective Serotonin Reuptake InhibitorSerotoninSertralineTechnologyTestingTherapeuticTherapeutic StudiesTimeWomanWorkangiogenesisbasechild bearingclinical applicationclinical efficacycopingdepressive symptomsdrug metabolismexperiencehigh throughput technologyimprovedinnovationmaternal depressionneonatenovel strategiespharmacokinetic modelpre-clinicalserotonin transporterskillssuccesssuicidal
项目摘要
DESCRIPTION (provided by applicant): Within the world of therapeutics, immense changes have occurred over the last fifty years that have benefited millions. The fundamental purpose of this application for an Obstetric Pharmacology Research Unit is to bring skills and technologies that have been key to the therapeutic revolution to the study of therapeutics in pregnancy. Within a strong academic clinical obstetric environment, we plan to exploit expertise and experience in the discipline of clinical pharmacology, which has been key to the success of the broad therapeutic revolution. We plan to build on the success of our pilot Center, entitled PREGMED, focused on research designed to deliver more individualized care to pregnant women and their children. Our proposal involves the synthesis of strong clinical obstetrics with 5 key cores: 1) a drug analytical laboratory to measure small amounts of drugs in pregnant women and their children; 2) a pharmacogenomic core laboratory that will use new high throughput technologies to improve both the targeting of therapies and our understanding of their biochemical basis 3) A computation and bioinformatics core to model pharmacokinetic, pharmacodynamic changes in concert with pharmacogenomic and other biomarker data. 4) An angiogenesis biomarker core aimed at following vascular effects of drugs in these women. 5) a bioethics core that we believe is integral to both our clinical and our basic/preclinical work. To demonstrate the collective value of these cores, we propose linked basic and clinical studies designed to test the vascular effects of the SSRI class of antidepressants in pregnant women. We hypothesize that SSRI metabolism increases during pregnancy resulting in a decrease in patient exposure to the SSRI and subsequent worsening of depressive symptoms and depression scores during pregnancy. To test this hypothesis we propose two aims: i) To investigate the pharmacokinetic parameters and clinical efficacy of SSRI therapy as pregnancy progresses and ii) to examine how genetic polymorphisms of drug metabolizing enzymes and the serotonin pathway impact SSRI disposition and efficacy.
描述(申请人提供):在治疗学的世界里,在过去的50年里发生了巨大的变化,使数百万人受益。申请产科药理学研究单位的基本目的是将对治疗革命至关重要的技能和技术带到怀孕治疗学研究中。在强大的学术临床产科环境中,我们计划利用临床药理学学科的专业知识和经验,这是广泛的治疗革命成功的关键。我们计划在我们名为PREGMED的试点中心的成功基础上再接再厉,该中心专注于旨在为孕妇及其子女提供更个性化护理的研究。我们的建议涉及合成具有5个关键核心的强大的临床产科:1)一个药物分析实验室,以测量孕妇及其子女中的少量药物;2)一个药物基因组核心实验室,它将使用新的高通量技术来改进治疗的靶向性和我们对其生物化学基础的了解;3)一个计算和生物信息学核心,用于模拟药代动力学、药效变化以及与药物基因组和其他生物标记物数据相一致的变化。4)血管生成生物标志物核心,旨在跟踪药物对这些女性的血管影响。5)我们认为对我们的临床和基础/临床前工作都不可或缺的生物伦理学核心。为了证明这些核心的集体价值,我们提出了相关的基础和临床研究,旨在测试SSRI类抗抑郁药在孕妇中的血管效应。我们假设怀孕期间SSRI代谢增加,导致患者暴露于SSRI的减少,并随后在怀孕期间抑郁症状和抑郁评分恶化。为了验证这一假说,我们提出了两个目标:i)研究SSRI治疗随着妊娠进展的药代动力学参数和临床疗效;ii)研究药物代谢酶基因多态和5-羟色胺途径如何影响SSRI的处置和疗效。
项目成果
期刊论文数量(9)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Patient attitudes toward genotyping in an urban women's health clinic.
城市妇女保健诊所患者对基因分型的态度。
- DOI:10.1097/aog.0b013e318187e77f
- 发表时间:2008
- 期刊:
- 影响因子:7.2
- 作者:Haas,DavidM;Renbarger,JamieL;Meslin,EricM;Drabiak,Katherine;Flockhart,David
- 通讯作者:Flockhart,David
Obstetric therapeutics-how pharmacogenetics may inform drug therapy for pregnant women in the future.
产科治疗——药物遗传学如何为未来孕妇的药物治疗提供信息。
- DOI:10.1097/ogx.0b013e3182a66180
- 发表时间:2013
- 期刊:
- 影响因子:6.2
- 作者:Haas,DavidM
- 通讯作者:Haas,DavidM
Antenatal corticosteroid therapy: current strategies and identifying mediators and markers for response.
产前皮质类固醇治疗:当前策略以及识别反应介质和标记物。
- DOI:10.1053/j.semperi.2014.08.018
- 发表时间:2014
- 期刊:
- 影响因子:3.4
- 作者:Falah,Nadia;Haas,DavidM
- 通讯作者:Haas,DavidM
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DAVID M. HAAS其他文献
DAVID M. HAAS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DAVID M. HAAS', 18)}}的其他基金
Machine learning approaches towards risk assessment and prediction of adverse pregnancy outcomes
用于风险评估和预测不良妊娠结局的机器学习方法
- 批准号:
10226370 - 财政年份:2020
- 资助金额:
$ 88.93万 - 项目类别:
Machine learning approaches towards risk assessment and prediction of adverse pregnancy outcomes
用于风险评估和预测不良妊娠结局的机器学习方法
- 批准号:
10453757 - 财政年份:2020
- 资助金额:
$ 88.93万 - 项目类别:
Machine learning approaches towards risk assessment and prediction of adverse pregnancy outcomes
用于风险评估和预测不良妊娠结局的机器学习方法
- 批准号:
10063323 - 财政年份:2020
- 资助金额:
$ 88.93万 - 项目类别:
Pharmacokinetics and modeling of betamethasone therapy in threatened preterm birth
先兆早产倍他米松治疗的药代动力学和模型
- 批准号:
9123871 - 财政年份:2016
- 资助金额:
$ 88.93万 - 项目类别:
Pharmacokinetics and modeling of betamethasone therapy in threatened preterm birth
先兆早产倍他米松治疗的药代动力学和模型
- 批准号:
10174278 - 财政年份:2016
- 资助金额:
$ 88.93万 - 项目类别:
Pharmacokinetics and modeling of betamethasone therapy in threatened preterm birth
先兆早产倍他米松治疗的药代动力学和模型
- 批准号:
9888973 - 财政年份:2016
- 资助金额:
$ 88.93万 - 项目类别:
Pregnancy as a Window to Future Cardiovascular Health
怀孕是未来心血管健康的窗口
- 批准号:
8576062 - 财政年份:2013
- 资助金额:
$ 88.93万 - 项目类别:
Dissecting the Genetic Etiology of Preterm Birth in Nulliparous Women
剖析未产妇早产的遗传病因
- 批准号:
8013029 - 财政年份:2010
- 资助金额:
$ 88.93万 - 项目类别:
Dissecting the Genetic Etiology of Preterm Birth in Nulliparous Women
剖析未产妇早产的遗传病因
- 批准号:
8204688 - 财政年份:2010
- 资助金额:
$ 88.93万 - 项目类别:
Dissecting the Genetic Etiology of Preterm Birth in Nulliparous Women
剖析未产妇早产的遗传病因
- 批准号:
8605888 - 财政年份:2010
- 资助金额:
$ 88.93万 - 项目类别:
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
$ 88.93万 - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
$ 88.93万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
$ 88.93万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
$ 88.93万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
$ 88.93万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
$ 88.93万 - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
$ 88.93万 - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
$ 88.93万 - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
$ 88.93万 - 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
- 批准号:
RGPIN-2018-04753 - 财政年份:2022
- 资助金额:
$ 88.93万 - 项目类别:
Discovery Grants Program - Individual